Springer Science and Business Media LLC
0340-3696
1432-069X
Cơ quản chủ quản: Springer Verlag , SPRINGER
Lĩnh vực:
DermatologyMedicine (miscellaneous)
Phân tích ảnh hưởng
Thông tin về tạp chí
Các bài báo tiêu biểu
Über „Porokeratosis Mibelli”
Tập 181 - Trang 532-548 - 1940
Auf Grund einer nochmaligen eingehenden histologischen Untersuchung mehrerer Fälle der eigenen Beobachtung von „Porokeratosis Mibelli” ergibt sich folgendes: Bei dem als „Porokeratosis Mibelli” bezeichneten Krankheitsbild handelt es sich nicht um eine vornehmliche Affektion der Schweißdrüsenporen und auch nicht um eine eigentliche Keratose, sondern um eine zentrifugal sich ausbreitende, zur Parakeratose führende Erkrankung des Oberflächenepithels mit akanthotischer und hyperkeratotischer Reaktion der Umgebung. Die an den Schweißdrüsen und Haarbälgen gefundenen Veränderungen sind Erscheinungen von untergeordneter Bedeutung. Sie ergeben sich zwangsläufig durch die Kontinuität des exzentrisch sich ausbreitenden Krankheitsvorganges. Die bisherige Bezeichnung der Krankheit ist irreführend; richtig ist: Parakeratosis centrifuga atrophicans oder einfacherParakeratosis annularis.
Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss
Tập 306 - Trang 413-418 - 2013
Female pattern hair loss (FPHL) is a common hair loss disorder in women and has a complex mode of inheritance. The etiopathogenesis of FPHL is largely unknown; however, it is hypothesized that FPHL and male pattern baldness [androgenetic alopecia (AGA)] share common genetic susceptibility alleles. Our recent findings indicate that the major AGA locus, an X-chromosome region containing the androgen receptor and the ectodysplasin A2 receptor (EDA2R) genes, may represent a common genetic factor underlying both early-onset FPHL and AGA. This gives further support for the widespread assumption of shared susceptibility loci for FPHL and AGA. However, we could not demonstrate association of further AGA risk loci, including 20p11, 1p36.22, 2q37.3, 7p21.1, 7q11.22, 17q21.31, and 18q21.1, with FPHL. Interestingly, a recent study identified four novel AGA risk loci in chromosomal regions 2q35, 3q25.1, 5q33.3, and 12p12.1. In particular, the 2q35 locus and its gene WNT10A point to an as-yet unknown involvement of the WNT signaling pathway in AGA. We hypothesized that the novel loci and thus also the WNT signaling may have a role in the etiopathogenesis of FPHL and therefore examined the role of these novel AGA risk loci in our FPHL samples comprising 440 German and 145 UK affected patients, 500 German unselected controls (blood donors), and 179 UK supercontrols. Patients and controls were genotyped for the top two single nucleotide polymorphisms at each of the four AGA loci. However, none of the genotyped variants displayed any significant association. In conclusion, the results of this study provide no support for the hypothesis that the novel AGA loci influence susceptibility to FPHL.
Systematic review of randomized controlled trials of topicals for actinic keratosis field therapy
- 2024
Cutaneous field cancerization in dermatology describes the anatomic region of photodamaged skin with actinic keratoses (AKs) or cutaneous squamous cell carcinoma (cSCC) that is surrounded by cellular atypia, forming a dysplastic field. The concept of field cancerization is especially relevant in dermatology, as actinic keratoses and the surrounding dysplastic region can progress to carcinomas, necessitating the treatment of the field. Recent research has focused on field-directed therapy using topical agents. This study aims to systematically review randomized controlled trials on topical treatments for actinic keratosis field cancerization, following the PRISMA guidelines. Clinical recommendations were based on the Oxford Centre for Evidence-Based Medicine. We identified 20 original randomized controlled trials for topical cutaneous field therapy. 0.5% 5-Fluorouracil/salicylic acid and 0.5% 5-fluorouracil received a clinical recommendation grade of A, while diclofenac sodium received a clinical recommendation grade of B. Calcipotriol/5-fluorouracil, Imiquimod, sunscreen combination therapies, and tirbanibulin received a recommendation grade of C. This review provides a framework for clinicians when considering topical treatments for patients with field cancerization.